塞奈吉明(Cenegermin-BKBJ) - 药物靶点：p75NTR_在研适应症：神经营养性角膜炎_专利_临床

概要

基本信息

药物类型

生长因子

别名

cenegermin、recombinant human Nerve Growth factor (rhNGF)、rhNGF

+ [4]

靶点

p75NTR

作用方式

激动剂、刺激剂

作用机制

p75NTR激动剂(低亲和力神经营养因子受体p75NTR激动剂)、神经元刺激剂

治疗领域

眼部疾病其他疾病

在研适应症

神经营养性角膜炎

非在研适应症

失明白内障角膜溃疡+ [7]

原研机构

Dompe Farmaceutici SpA

在研机构

Dompe Farmaceutici SpAJace Pharma Pty Ltd.

非在研机构-

权益机构

Dompe Farmaceutici SpA

Tanner Pharma Group, Inc.Dompé Pharmaceutici Spa

+ [1]

最高研发阶段批准上市

首次获批日期

欧盟 (2017-07-06),

神经营养性角膜炎

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、快速通道 (美国)、孤儿药 (美国)、孤儿药 (澳大利亚)、临床急需境外新药 (中国)、优先审评 (澳大利亚)、局长国家优先审评券 (美国)

登录后查看时间轴

结构/序列

Sequence Code 28791467

来源: *****

关联

28

项与塞奈吉明相关的临床试验

NCT06411145

/ Withdrawn临床4期

A Prospective, Multicenter Trial to Evaluate Efficacy and Safety of Cenegermin-bkbj (20 mcg/mL) Ophthalmic Solution on Corneal Thickness Via Anterior Segment Optical Coherence Tomography (AS-OCT) in Stage 3 Neurotrophic Keratitis

Primary Objective:
To assess the efficacy of cenegermin-bkbj (20 mcg/mL) ophthalmic solution on overall corneal thickness via AS-OCT in patients with stage 3 neurotrophic keratitis with respect to change from baseline at weeks 4, 8, and 16.
Secondary Objectives:
To assess the effects of cenegermin-bkbj (20 mcg/mL) ophthalmic solution on corneal stromal thickness via AS-OCT in patients with stage 3 neurotrophic keratitis with respect to change from baseline at weeks 4, 8, and 16.
To assess the effects of cenegermin-bkbj (20 mcg/mL) ophthalmic solution on corneal stromal reflectivity via AS-OCT in patients with stage 3 neurotrophic keratitis with respect to change from baseline at weeks 4, 8, and 16.
To assess the effects of cenegermin-bkbj (20 mcg/mL) ophthalmic solution on corneal sensitivity via Cochet-Bonnet aesthesiometer in the center of the lesion with respect to change from baseline at weeks 4, 8, and 16.

开始日期2024-04-26

申办/合作机构

Dompe Farmaceutici SpA

NCT06244316

/ Completed临床2期

A 4-Week, Phase II, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study With 4 Weeks of Follow-Up to Evaluate Safety and Efficacy of a New Formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution at Two Different Concentrations in Patients With Dry Eye Disease

The purpose of this study is to evaluate the safety and efficacy of two different concentrations of the new formulation of rhNGF ophthalmic solution versus vehicle, in order to demonstrate superiority of at least one of the two concentrations over vehicle in the improvement of ocular symptoms of dry eye in participants with dry eye disease (DED). The rhNGF ophthalmic solution, or vehicle, will be administered as one drop in each eye, three times a day, for 4 weeks. Participants will attend a total of 5 study visits from screening through end of the study (Week 8), which will include eye exams and questionnaires.

开始日期2024-01-22

申办/合作机构

Dompe Farmaceutici SpA

NCT05552261

/ CompletedN/A

A Long-term Extension Study to Evaluate the Safety and Efficacy of OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj Ophthalmic Solution in Patients With Stage 1 Neurotrophic Keratitis Who Enrolled in the DEFENDO Study (NGF0120)

Primary Objective
To evaluate the long-term safety and efficacy (healing) of OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in Stage 1 neurotrophic keratitis (NK) patients who enrolled in the DEFENDO study.
Secondary Objective
To evaluate the long-term efficacy of OXERVATE® 0.002% (20 mcg/mL) cenergemin-bkbj ophthalmic solution in terms of corneal sensitivity, Schirmer I test, tear film break-up time (TFBUT), best corrected distance visual acuity (BCDVA), and quality of life at 24 and 30 months post-treatment

开始日期2023-02-01

申办/合作机构

Dompe Farmaceutici SpA

100 项与塞奈吉明相关的临床结果

登录后查看更多信息

100 项与塞奈吉明相关的转化医学

登录后查看更多信息

100 项与塞奈吉明相关的专利（医药）

登录后查看更多信息

163

项与塞奈吉明相关的文献（医药）

2025-12-01·Ophthalmology and Therapy

Cenegermin for the Treatment of Moderate or Severe Neurotrophic Keratopathy: Results from a Prospective, Phase IV, Open-Label Study in China

Article

作者: Li, Suxia ; Siri, Giacomo ; Xu, Jianjiang ; Yuan, Jin ; Shi, Weiyun ; Hauswirth, Scott G ; Pan, Zhiqiang ; Mantelli, Flavio

INTRODUCTION:

Neurotrophic keratopathy (NK) is a rare degenerative disease that can lead to epithelial breakdown, corneal ulceration, and potentially perforation and vision loss. Cenegermin is a recombinant human nerve growth factor approved for stage 2/3 NK, though data on its efficacy outside of United States/European populations are limited.

METHODS:

This prospective, phase IV, open-label, multicenter study investigated the efficacy, safety, and pharmacokinetics (PK) of cenegermin eye drops in Chinese patients with stage 2/3 NK in a routine clinical setting (CTR20220066). Patients received cenegermin eye drops (20 mcg/mL; 6 times/day at 2-hour intervals) for 8 weeks with follow-up to week 56. The primary endpoint was corneal healing at week 8 per investigator assessment. Additional endpoints included lesion worsening, corneal healing through week 56, safety, and PK.

RESULTS:

Of the 28 patients receiving cenegermin, 22/26 (84.6%, 95% confidence interval 65.1-95.6%; 2 missing) achieved corneal healing at week 8; 3/22 (13.6%) reported recurrence during 48-week follow-up but 20/22 (90.9%) were healed at week 56; and 2/28 (7.1%) experienced lesion worsening during 8-week treatment. In addition, 25/28 (89.3%) experienced ≥ 1 treatment-emergent adverse event (TEAE); for the majority (23/28, 82.2%) of these patients, TEAEs were mild/moderate. None of the serious TEAEs reported by 10 (35.7%) patients were assessed as related to cenegermin or led to treatment discontinuation. Eye pain was the most common cenegermin-related TEAE (5/28, 17.9%), primarily limited to the treatment period.

CONCLUSIONS:

These findings demonstrate that cenegermin eye drops are an effective, generally well-tolerated treatment in Chinese patients with stage 2/3 NK, supporting their use in this patient population.

TRIAL REGISTRATION:

CTR20220066.

2025-12-01·EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Safety and pharmacokinetics of escalating doses of recombinant human nerve growth factor eye drops (HT006.2.2) in healthy subjects

Article

作者: Hu, Xiaojun ; Ni, Siyang ; Lu, Laichun ; Jie, Ying ; Lu, Huan ; Pang, Hongyan ; Tang, Huadong ; Wu, Feng ; Yu, Wei ; Jiao, Ying ; Dai, Yuyang ; Han, Ying

BACKGROUND:

HT006.2.2 is a kind of recombinant human nerve growth factor (rhNGF) eye drop with the potential to treat neurotrophic keratitis.

OBJECTIVE:

To evaluate the safety, immunogenicity, and pharmacokinetic (PK) characteristics of HT006.2.2 eye drops in Chinese healthy volunteers.

METHODS:

This study was divided into three parts. In Part A (single-dose) and Part B (multi-dose), four dose groups were per-specified: 5 µg/mL, 20 µg/mL, 60 µg/mL and 120 µg/mL. Each dose group comprised eight subjects randomized in a 3:1 ratio to receive the HT006.2.2 or placebo. Serum samples were collected for systemic PK analysis and anti-drug antibody (ADA) detection. The Part C comprised two single-dose groups (20 µg/mL and 60 µg/mL), and tear samples were collected at preset time points for tear fluid PK analysis. The drug mass per gram of tears (unit: µg/g) was calculated and used as the drug concentration to recalculate the PK parameters. Safety was evaluated via vital signs monitoring, 12-lead electrocardiogram, clinical laboratory tests, and ophthalmologic assessments (ocular symptoms and signs, slit-lamp microscopy, corneal fluorescein sodium staining, intraocular pressure measurement, and best-corrected visual acuity). Adverse events were collected following the initial administration of the investigational drug and were defined as treatment-emergent adverse events (TEAEs).

RESULTS:

This study enrolled a total of 163 subjects, with 161 receiving the medication and completing the study as planned. HT006.2.2 showed favorable tolerance across both single-dose and multiple-dose parts. At the highest dose of 120 µg/mL, no maximum tolerated dose (MTD) was reached. No discernible dose-response relationship was identified in the incidence of TEAEs across dosage groups, with the total TEAE rate in HT006.2.2 groups remaining non-exceeding that of the placebo group. Ocular TEAEs included corneal vital dye staining, eye itching, eye pain, conjunctival hyperemia, and decreased visual acuity. In addition, no HT006.2.2 or ADA was detected in the peripheral blood of healthy subjects. Tear fluid PK analysis of HT006.2.2 (20 µg/mL) showed time to peak concentration (T_max) of 0.17 h, mean peak concentration (C_max) of 3.63 ± 2.06 µg/g, elimination half-life (t_1/2) of 4.21 h.

CONCLUSIONS:

HT006.2.2 eye drops exhibited favorable safety in Chinese healthy subjects, with localized ocular distribution, no systemic exposure, and no detectable ADAs. These findings support the continuation of clinical development for HT006.2.2 in China.

2025-10-01·Ocular Surface

Prospective consecutive case series of patients with neurotrophic keratopathy associated with unilateral total limbal stem cell deficiency caused by severe ocular surface burns

Article

作者: Figueiredo, Francisco C ; Mudhar, Hardeep-Singh ; Lako, Majlinda ; Stefanache, Teodor ; Baylis, Oliver J ; Figueiredo, Gustavo S

INTRODUCTION:

Limbal stem cell deficiency (LSCD) is commonly caused by ocular surface burns. Corneal nerve damage, often due to infection, inflammation, trauma, leads to neurotrophic keratopathy (NK). This study investigates corneal sensation and nerve damage in patients with unilateral total LSCD before and after autologous cultivated limbal epithelial transplantation (Auto-CLET).

METHODS:

This prospective, single-centre case series included patients with unilateral total LSCD due to severe burns treated at Royal Victoria Infirmary, UK, between June 2012 and January 2018. Corneal sensation was assessed using Cochet-Bonnet aesthesiometry at baseline and 6 months post-Auto-CLET, and in vivo confocal microscopy (IVCM) was used to examine nerve regeneration.

RESULTS:

Twenty-three patients (19 males, 4 females) received Auto-CLET. Successful restoration of the ocular surface was achieved in all patients, confirmed by slit lamp examination, impression cytology, and IVCM at follow-ups up to 36 months. Baseline best corrected visual acuity was 1.67 logMAR in the affected eye compared to a mean of -0.08 in the healthy eye. Corneal aesthesiometry in LSCD eyes averaged 9.13 mm at baseline, increasing to 12.0 mm at 6 months post-Auto-CLET, though this change was not statistically significant (p = 0.26). IVCM revealed no regeneration of corneal nerves at any follow-up intervals, indicating persistent nerve damage.

CONCLUSIONS:

Despite successful ocular surface restoration, corneal nerve damage persisted, leaving patients at risk of persistent NK. To address this, we strongly suggest continuous topical treatment with blood derived products, such as serum eye drops, but also newly developed therapies such as IGF and rhNGF class of drugs.

70

项与塞奈吉明相关的新闻（医药）

2025-12-12

·搜狐新闻

海特生物跌0.94%，成交额8869.15万元，近5日主力净流入-2780.33万

来源：新浪证券-红岸工作室12月12日，海特生物跌0.94%，成交额8869.15万元，换手率2.55%，总市值37.33亿元。异动分析重组蛋白+细胞免疫治疗+创新药+CRO概念+眼科医疗1、公司2023年10月30日互动：CPT是全球首个完成多发性骨髓瘤Ⅲ期临床试验的针对TRAIL的死亡受体4和死亡受体5靶点的促凋亡激动剂，同靶点药物目前国内外均无上市。CPT作为一种重组蛋白类抗肿瘤药物，属于Ⅰ类治疗性新生物制品，可为多发性骨髓瘤患者提供一种新的治疗方案。2、根据2025年6月13日投资者关系管理信息：主流的血液病医院的CAR-T治疗过程中，而包括中国医学科学院血液病医院、西部战区总医院在内的国内一线血液病医院也在积极与我司合作开展埃普奈明用于CAR-T前桥接化疗及CAR-T后的维持治疗等方向的临床试验研究。3、主导产品金路捷（注射用鼠神经生长因子）属国家一类新生物制品，为全球第一个获得政府批准上市的神经损伤类疾病用药。4、武汉海特生物制药股份有限公司的主营业务是大分子生物药、小分子化学药、原料药与医药中间体的生产销售，同时也为国内外的制药企业提供制剂和原料药的CRO、CMO和CDMO技术服务。5、2023年10月9日公告：公司收到国家药品监督管理局核准签发的HT006.2.2滴眼液的《药物临床试验批准通知书》，HT006.2.2滴眼液是公司开发的具有独立自主知识产权的重组人神经生长因子眼用制剂，靶向作用于原肌球蛋白受体激酶A和p75神经营养因子受体。通过制剂处方开发及优化研究，本项目制剂稳定性优于同类产品Cenegermin，临床拟用于中、重度神经营养性角膜炎治疗。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入-625.32万，占比0.07%，行业排名43/52，连续3日被主力资金减仓；所属行业主力净流入-9846.95万，当前无连续增减仓现象，主力趋势不明显。区间今日近3日近5日近10日近20日主力净流入-625.32万-1727.51万-2780.33万-5596.38万-1.24亿主力持仓主力没有控盘，筹码分布非常分散，主力成交额2974.43万，占总成交额的7.12%。技术面：筹码平均交易成本为32.08元该股筹码平均交易成本为32.08元，近期筹码减仓，但减仓程度减缓；目前股价靠近压力位28.81，谨防压力位处回调，若突破压力位则可能会开启一波上涨行情。公司简介资料显示，武汉海特生物制药股份有限公司位于湖北省武汉经济技术开发区海特科技园，成立日期1992年4月8日，上市日期2017年8月8日，公司主营业务涉及创新生物药的研发、生产和销售,同时提供小分子化学医药研发、受托药品生产等相关服务。主营业务收入构成为：技术服务收入57.20%，注射用鼠神经生长因子25.59%，注射用埃普奈明17.04%，其他(补充)0.17%。海特生物所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：CRO概念、生物医药、创新药、眼科概念、并购重组等。截至11月28日，海特生物股东户数1.90万，较上期减少4.26%；人均流通股6419股，较上期增加4.45%。2025年1月-9月，海特生物实现营业收入4.22亿元，同比减少6.45%；归母净利润-1.58亿元，同比减少297.78%。分红方面，海特生物A股上市后累计派现8523.06万元。近三年，累计派现1701.63万元。风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建议。返回搜狐，查看更多

2025-12-11

·搜狐新闻

海特生物跌1.57%，成交额1.04亿元，近5日主力净流入-2361.50万

来源：新浪证券-红岸工作室12月11日，海特生物跌1.57%，成交额1.04亿元，换手率2.94%，总市值37.68亿元。异动分析重组蛋白+细胞免疫治疗+创新药+CRO概念+眼科医疗1、公司2023年10月30日互动：CPT是全球首个完成多发性骨髓瘤Ⅲ期临床试验的针对TRAIL的死亡受体4和死亡受体5靶点的促凋亡激动剂，同靶点药物目前国内外均无上市。CPT作为一种重组蛋白类抗肿瘤药物，属于Ⅰ类治疗性新生物制品，可为多发性骨髓瘤患者提供一种新的治疗方案。2、根据2025年6月13日投资者关系管理信息：主流的血液病医院的CAR-T治疗过程中，而包括中国医学科学院血液病医院、西部战区总医院在内的国内一线血液病医院也在积极与我司合作开展埃普奈明用于CAR-T前桥接化疗及CAR-T后的维持治疗等方向的临床试验研究。3、主导产品金路捷（注射用鼠神经生长因子）属国家一类新生物制品，为全球第一个获得政府批准上市的神经损伤类疾病用药。4、武汉海特生物制药股份有限公司的主营业务是大分子生物药、小分子化学药、原料药与医药中间体的生产销售，同时也为国内外的制药企业提供制剂和原料药的CRO、CMO和CDMO技术服务。5、2023年10月9日公告：公司收到国家药品监督管理局核准签发的HT006.2.2滴眼液的《药物临床试验批准通知书》，HT006.2.2滴眼液是公司开发的具有独立自主知识产权的重组人神经生长因子眼用制剂，靶向作用于原肌球蛋白受体激酶A和p75神经营养因子受体。通过制剂处方开发及优化研究，本项目制剂稳定性优于同类产品Cenegermin，临床拟用于中、重度神经营养性角膜炎治疗。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入-526.48万，占比0.05%，行业排名36/52，连续3日被主力资金减仓；所属行业主力净流入2.75亿，连续3日被主力资金增仓。区间今日近3日近5日近10日近20日主力净流入-526.48万-1213.81万-2361.50万-4935.73万-1.11亿主力持仓主力没有控盘，筹码分布非常分散，主力成交额2365.74万，占总成交额的5.69%。技术面：筹码平均交易成本为32.17元该股筹码平均交易成本为32.17元，近期该股有吸筹现象，但吸筹力度不强；目前股价靠近压力位28.90，谨防压力位处回调，若突破压力位则可能会开启一波上涨行情。公司简介资料显示，武汉海特生物制药股份有限公司位于湖北省武汉经济技术开发区海特科技园，成立日期1992年4月8日，上市日期2017年8月8日，公司主营业务涉及创新生物药的研发、生产和销售,同时提供小分子化学医药研发、受托药品生产等相关服务。主营业务收入构成为：技术服务收入57.20%，注射用鼠神经生长因子25.59%，注射用埃普奈明17.04%，其他(补充)0.17%。海特生物所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：生物医药、创新药、CRO概念、眼科概念、原料药等。截至11月28日，海特生物股东户数1.90万，较上期减少4.26%；人均流通股6419股，较上期增加4.45%。2025年1月-9月，海特生物实现营业收入4.22亿元，同比减少6.45%；归母净利润-1.58亿元，同比减少297.78%。分红方面，海特生物A股上市后累计派现8523.06万元。近三年，累计派现1701.63万元。风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建议。返回搜狐，查看更多

2025-12-11

·今日头条

海特生物双轨布局应对行业变革锚定先进治疗药创新机遇

武汉海特生物制药股份有限公司董事会秘书杨坤日前表示，面对医药行业政策、资金等方面的变化，公司通过“化药仿制药+创新药”双轨布局应对行业变革，同时锚定细胞与基因治疗（CGT）等先进治疗技术方向，探索创新药机会。 1. 双轨布局应对行业变化杨坤指出，当前医药行业在政策、资金各方面均面临较大变化，公司已充分认识到这些变化并调整策略。具体来看，公司的布局分为两条主线：一是在传统化药领域应对集采影响，二是在创新药领域布局前沿技术。 2. 仿制药借集采切入化药市场在化药方面，针对国家带量采购政策对传统药物市场规模的影响，公司立项了一批仿制药项目，并积极申报国家集采，希望通过集采通道快速切入化药市场，扩大产品基础和市场份额。 3. 创新药锚定前沿技术方向在创新药领域，公司主要通过与科学家、科研机构合作，或参股具有技术潜力的公司，布局前沿领域的创新药品种。目前，公司的创新药项目涵盖神经疾病、肿瘤、眼科等多个领域： - 重组变构人肿瘤坏死因子相关凋亡诱导配体（CPT）是公司与北京沙东联合开发的Ⅰ类生物制品，为全球首个完成多发性骨髓瘤Ⅲ期临床试验的TRAIL靶点促凋亡激动剂，同靶点药物国内外均无上市； - HT006.2.2滴眼液是公司开发的重组人神经生长因子眼用制剂，靶向原肌球蛋白受体激酶A和p75神经营养因子受体，制剂稳定性优于同类产品Cenegermin，临床拟用于中、重度神经营养性角膜炎治疗，已获国家药监局临床试验批准。 4. CGT成未来重点布局领域杨坤表示，从技术演变路径来看，单抗、双抗、ADC等靶向药物的商业化成功，充分证明了CGT方向的技术可行性，未来商业价值可期，因此公司将CGT作为未来重点布局的方向。 5. 参股公司推进基因疗法临床公司通过参股方式布局的前沿创新药项目已取得进展。其参股公司中眸医疗科技（武汉）有限公司的“ZM-02眼用注射液治疗晚期视网膜色素变性的药物管线”，近日获得美国食品药品监督管理局（FDA）临床试验批准（受理号：IND32046）。 ZM-02是新一代光遗传学基因疗法，通过单次玻璃体腔注射将新型光敏蛋白基因递送至视网膜细胞，使患者在缺乏功能性光感受器的情况下仍能感知光信号。与传统针对特定基因突变的疗法不同，该疗法采用非基因突变位点依赖性策略，可广泛适用于遗传性及获得性视网膜退行性疾病（如年龄相关性黄斑变性）。临床前研究显示，ZM-02在视网膜色素变性小鼠模型中实现稳定蛋白表达，表现出卓越的光敏感度及视功能恢复能力；正在进行的首次人体MOON临床试验（NCT06292650）显示，该疗法可显著改善晚期视网膜色素变性（RP）患者的视力及生活质量，且具有良好的安全性。2024年10月，ZM-02已获得FDA孤儿药资格认定。

100 项与塞奈吉明相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	塞奈吉明	S01XA24	DB13926

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
神经营养性角膜炎	欧盟	Dompe Farmaceutici SpA	2017-07-06
神经营养性角膜炎	冰岛	Dompe Farmaceutici SpA	2017-07-06
神经营养性角膜炎	列支敦士登	Dompe Farmaceutici SpA	2017-07-06
神经营养性角膜炎	挪威	Dompe Farmaceutici SpA	2017-07-06

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
干眼综合征	临床3期	美国	Dompe Farmaceutici SpA	2022-01-19
干眼综合征	临床3期	意大利	Dompe Farmaceutici SpA	2022-01-19
干燥综合征	临床3期	美国	Dompe Farmaceutici SpA	2022-01-19
干燥综合征	临床3期	意大利	Dompe Farmaceutici SpA	2022-01-19
干燥综合征性角膜结膜炎	临床2期	美国	Dompe Farmaceutici SpA	2017-01-20
白内障	临床2期	意大利	Dompe Farmaceutici SpA	2017-01-12
失明	临床2期	意大利	Dompe Farmaceutici SpA	2015-05-01
黄斑水肿	临床2期	意大利	Dompe Farmaceutici SpA	2015-05-01
视网膜色素变性	临床2期	意大利	Dompe Farmaceutici SpA	2015-05-01
角膜溃疡	临床2期	法国	Dompe Farmaceutici SpA	2013-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03982368 (Pubmed) 人工标引	临床2期	干眼综合征	-	Cenegermin 20 mcg/mL t.i.d.	醖衊獵構鏇夢窪餘壓餘(膚積鏇觸繭憲選積積範) = 繭醖膚鹹襯鹹艱製衊衊壓廠網憲醖醖遞網簾築 (糧糧構簾願鹹糧範衊鹽 ) 更多	不佳	2024-07-17
				Cenegermin 20 mcg/mL b.i.d.	醖衊獵構鏇夢窪餘壓餘(膚積鏇觸繭憲選積積範) = 鏇製築壓鏇餘繭鹹繭鹹壓廠網憲醖醖遞網簾築 (糧糧構簾願鹹糧範衊鹽 ) 更多
NCT04485546 (DEFENDO, Pubmed)	临床4期	神经营养性角膜炎	37	Cenegermin 20 mcg/ml	鑰鏇鹹餘鏇膚獵鹹夢壓(構網願鹽構憲襯襯廠襯) = 簾壓範窪鬱繭繭憲網憲鏇網鹹積醖憲壓廠膚憲 (獵廠觸構齋選壓蓋築淵, 5.1 ~ 31.9) 更多	-	2024-02-01
NCT04485546 (DEFENDO, CTgov)	临床4期	神经营养性角膜炎	37	cenegermin-bkbj	鹽鑰夢鬱憲壓簾積憲構 = 簾網糧艱鹽繭鹹膚鹽鏇製顧齋選鹹淵繭範簾鏇 (鬱願願壓鑰繭鏇鹽願夢, 衊淵製顧製鑰鹹糧艱窪 ~ 簾蓋繭鹹鬱醖夢膚構鹹) 更多	-	2023-06-23
NCT04552730 (Pubmed \| Ther Adv Ophthalmol)	N/A	边缘干细胞缺乏症	5	Cenegermin	鹽廠糧窪選糧壓範築醖(觸壓鹽蓋築餘廠獵齋蓋) = 顧築餘醖糧壓選遞獵積餘廠築鬱製遞選構鹽構 (願製夢選遞糧艱齋網醖 ) 更多	-	2022-01-01
NCT02855450 (NGF-Glaucoma, CTgov)	临床1期	青光眼	60	rhNGF (rhNGF)	艱蓋淵襯構鏇觸構獵鬱 = 觸艱觸選獵夢艱膚醖窪艱鹽鏇範襯鹹獵糧窪壓 (網簾獵構顧選簾網鏇觸, 窪糧廠壓製築廠憲衊襯 ~ 齋憲顧繭餘築醖築餘願) 更多	-	2020-11-25
				Vehicle (Vehicle)	艱蓋淵襯構鏇觸構獵鬱 = 選簾構範範鬱壓獵簾築艱鹽鏇範襯鹹獵糧窪壓 (網簾獵構顧選簾網鏇觸, 構積遞壓醖衊鏇廠觸膚 ~ 鏇鏇繭鹹鹹蓋壓製襯網) 更多
NCT03836859 (CTgov)	临床1期	-	30	rhNGF 20μg/mL (rhNGF 20μg/mL)	膚夢膚夢築廠鏇選壓壓 = 醖範廠餘壓積夢觸鏇淵蓋構顧壓廠糧選衊壓築 (選鹹積淵積構廠顧願簾, 齋衊壓淵鬱製遞襯選獵 ~ 製餘選繭遞獵網構鑰觸) 更多	-	2020-06-11
				Placebo (Placebo)	膚夢膚夢築廠鏇選壓壓 = 壓簾鏇範網網觸餘衊醖蓋構顧壓廠糧選衊壓築 (選鹹積淵積構廠顧願簾, 築醖糧鹹遞襯鬱夢觸廠 ~ 淵夢簾鹹製築鹹願鏇獵) 更多
NCT02101281 (Pubmed \| Br J Ophthalmol) 人工标引	临床2期	干眼综合征	40	rhNGF (20 µg/mL)	鏇繭膚願願襯簾醖選構(願願製繭蓋壓簾鏇築築) = 憲夢繭願淵艱簾糧遞簾膚鹽蓋築簾襯鏇窪夢夢 (夢積齋網膚顧鬱網膚遞, 26.2) 更多	积极	2020-01-01
				rhNGF (40 µg/mL)	鏇繭膚願願襯簾醖選構(願願製繭蓋壓簾鏇築築) = 鑰糧築鏇壓艱窪築鏇獵膚鹽蓋築簾襯鏇窪夢夢 (夢積齋網膚顧鬱網膚遞, 26.4) 更多
NCT02101281 (CTgov)	临床2期	干眼综合征	40	rhNGF 20 µg/mL (Group 1 - rhNGF 20 μg/mL)	艱選網艱築積憲構觸願 = 窪齋憲顧構願鬱顧願觸衊餘窪廠淵構願願網鬱 (構觸獵醖廠憲繭憲築窪, 鹹廠襯願齋憲餘衊願餘 ~ 範淵選觸襯鹽壓壓製壓) 更多	-	2019-08-07
				rhNGF 4 µg/mL (Group 2 - rhNGF 4 μg/mL)	艱選網艱築積憲構觸願 = 顧簾鏇選範獵襯鏇簾顧衊餘窪廠淵構願願網鬱 (構觸獵醖廠憲繭憲築窪, 糧選顧淵廠膚糧壓壓襯 ~ 觸齋鹽壓選積糧廠齋襯) 更多
NCT03035864 (CTgov)	临床2期	白内障	180	rhNGF (rhNGF 20 µg/ml)	築蓋廠築製齋夢齋淵鏇(鹹築鑰齋範夢壓衊窪壓) = 築醖齋膚蓋蓋選夢餘鏇觸積顧淵餘膚鑰膚遞鑰 (襯鑰膚蓋築淵獵鑰觸繭, 24.85) 更多	-	2019-07-22
				Vehicle (Vehicle)	築蓋廠築製齋夢齋淵鏇(鹹築鑰齋範夢壓衊窪壓) = 獵範築憲築遞蓋襯齋鑰觸積顧淵餘膚鑰膚遞鑰 (襯鑰膚蓋築淵獵鑰觸繭, 26.04) 更多
NCT02110225 (Lumos, CTgov)	临床1/2期	视网膜色素变性	50	rhNGF 60 µg/ml eye drops solution (rhNGF 60µg/ml)	餘膚網鬱鏇衊蓋願蓋糧 = 鬱衊蓋築範繭網醖鏇壓衊廠構製淵鏇壓顧顧築 (鬱鹹鹽鏇選衊餘願鑰鑰, 願齋膚鹽夢憲膚廠網範 ~ 憲淵鹽餘蓋廠觸鹹構鹽) 更多	-	2019-07-11
				rhNGF (rhNGF 180 µg/ml)	餘膚網鬱鏇衊蓋願蓋糧 = 鹽壓鬱餘蓋選構齋獵蓋衊廠構製淵鏇壓顧顧築 (鬱鹹鹽鏇選衊餘願鑰鑰, 繭鏇願獵選壓鹽遞繭壓 ~ 醖顧夢鑰鏇願鑰鏇襯鹽) 更多